JP2023553877A - アミロイド疾患を診断する方法 - Google Patents

アミロイド疾患を診断する方法 Download PDF

Info

Publication number
JP2023553877A
JP2023553877A JP2023533877A JP2023533877A JP2023553877A JP 2023553877 A JP2023553877 A JP 2023553877A JP 2023533877 A JP2023533877 A JP 2023533877A JP 2023533877 A JP2023533877 A JP 2023533877A JP 2023553877 A JP2023553877 A JP 2023553877A
Authority
JP
Japan
Prior art keywords
amyloid
organ
reactive agent
ratio
heart
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023533877A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023553877A5 (https=
JPWO2022120378A5 (https=
Inventor
ジョナサン・エス・ウォール
ロバート・エリック・ヘイデル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Tennessee Research Foundation
Original Assignee
University of Tennessee Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Tennessee Research Foundation filed Critical University of Tennessee Research Foundation
Publication of JP2023553877A publication Critical patent/JP2023553877A/ja
Publication of JP2023553877A5 publication Critical patent/JP2023553877A5/ja
Publication of JPWO2022120378A5 publication Critical patent/JPWO2022120378A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0453—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Optics & Photonics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medical Treatment And Welfare Office Work (AREA)
  • Measuring And Recording Apparatus For Diagnosis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
JP2023533877A 2020-12-04 2021-12-03 アミロイド疾患を診断する方法 Pending JP2023553877A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063121779P 2020-12-04 2020-12-04
US63/121,779 2020-12-04
PCT/US2021/072729 WO2022120378A1 (en) 2020-12-04 2021-12-03 Method for diagnosing amyloid diseases

Publications (3)

Publication Number Publication Date
JP2023553877A true JP2023553877A (ja) 2023-12-26
JP2023553877A5 JP2023553877A5 (https=) 2024-12-10
JPWO2022120378A5 JPWO2022120378A5 (https=) 2024-12-10

Family

ID=79170797

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023533877A Pending JP2023553877A (ja) 2020-12-04 2021-12-03 アミロイド疾患を診断する方法

Country Status (10)

Country Link
US (1) US20240003912A1 (https=)
EP (1) EP4255508A1 (https=)
JP (1) JP2023553877A (https=)
KR (1) KR20230144525A (https=)
CN (1) CN117460543A (https=)
AU (1) AU2021393591A1 (https=)
CA (1) CA3200167A1 (https=)
IL (1) IL302834A (https=)
MX (1) MX2023006568A (https=)
WO (1) WO2022120378A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025212955A1 (en) * 2024-04-05 2025-10-09 University Of Tennessee Research Foundation Method for diagnosing amyloid diseases

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016032949A1 (en) * 2014-08-26 2016-03-03 University Of Tennessee Research Foundation Targeting immunotherapy for amyloidosis

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3939350A (en) 1974-04-29 1976-02-17 Board Of Trustees Of The Leland Stanford Junior University Fluorescent immunoassay employing total reflection for activation
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4277437A (en) 1978-04-05 1981-07-07 Syva Company Kit for carrying out chemically induced fluorescence immunoassay
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
US4900540A (en) 1983-06-20 1990-02-13 Trustees Of The University Of Massachusetts Lipisomes containing gas for ultrasound detection
EP0231091B1 (en) 1986-01-24 1993-03-31 Children's Hospital Medical Center Stable emulsions of highly fluorinated organic compound
MX9205298A (es) 1991-09-17 1993-05-01 Steven Carl Quay Medios gaseosos de contraste de ultrasonido y metodo para seleccionar gases para usarse como medios de contraste de ultrasonido
EP4058479A4 (en) * 2019-11-15 2024-02-28 University of Tennessee Research Foundation MODIFIED IMMUNOLOBULINES FOR TARGETING AMYLOID DEPOSITS
AU2021208630A1 (en) * 2020-01-17 2022-07-21 University Of Tennessee Research Foundation Chimeric antigen receptors for removal of amyloid

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016032949A1 (en) * 2014-08-26 2016-03-03 University Of Tennessee Research Foundation Targeting immunotherapy for amyloidosis

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BLOOD, vol. 134, no. 1, JPN6026001928, 2019, pages 3034, ISSN: 0005781632 *
MOLECULES, vol. 20, no. 5, JPN6026001929, 2015, pages 7657 - 7682, ISSN: 0005781631 *

Also Published As

Publication number Publication date
EP4255508A1 (en) 2023-10-11
IL302834A (en) 2023-07-01
AU2021393591A9 (en) 2024-10-03
CN117460543A (zh) 2024-01-26
US20240003912A1 (en) 2024-01-04
WO2022120378A1 (en) 2022-06-09
AU2021393591A1 (en) 2023-07-06
KR20230144525A (ko) 2023-10-16
CA3200167A1 (en) 2022-06-09
MX2023006568A (es) 2023-06-16

Similar Documents

Publication Publication Date Title
US8808666B2 (en) Peptides that specifically target amyloid deposits
Dezutter et al. 99mTc-MAMA-chrysamine G, a probe for beta-amyloid protein of Alzheimer’s disease
US5837473A (en) Methods of screening for agents affecting the deposition of β-amyloid peptides on amyloid plaques in human tissue
US20240082434A1 (en) Contrast agents, methods for preparing contrast agents, and methods of imaging
US20110097267A1 (en) Compositions for imaging pain and stress in vivo
US20040223912A1 (en) Compositions and methods for non-invasive imaging of soluble beta-amyloid
JP2023553877A (ja) アミロイド疾患を診断する方法
CA2614486C (en) Contrast agent comprising a scaffold protein and a metal ion chelating site integrated therein
AU2024339036A1 (en) Method for diagnosing amyloid diseases
Martin et al. A tale of two tracers-Amyloid imaging with investigational radiotracers iodine (124I) evuzamitide and 99mTc-p5+ 14 (AT-05)
US20150050213A1 (en) Compositions and methods for imaging inflammation of traumatic brain injury
US20130266513A1 (en) Imaging of meningiomas using phingylbenzothiazole, stilbene, or biphenylalkyne derivatives
Signore et al. Biological imaging for the diagnosis of inflammatory conditions
EA051394B1 (ru) Способ диагностики амилоидозов
KR102423777B1 (ko) 전립선 특이막항원 표적용 화합물 및 이의 용도
WO2025212955A1 (en) Method for diagnosing amyloid diseases
Meyer et al. 123I‐antileukoproteinase scintigraphy reveals microscopic cartilage alterations in the contralateral knee joint of rats with “monarticular” antigen‐induced arthritis
Blaufox Renal Radiopharmaceuticals
KR102778319B1 (ko) Egfr l858r 돌연변이를 포함하는 암을 표적하는 화합물 및 이의 용도
US20090208408A1 (en) Use of vcam-1 ligands for detecting and/or treating cardiovascular diseases
Bickel Diagnosis of CAA during Life: Neuroimaging of CAA
Janczak The role of radiopharmaceuticals in diagnosis of melanoma malignum
BICKEL Neuroimaging of CAA
Maina Cardiovascular: Diagnosis-Perfusion
Antoni et al. 11C-PIB and PET for the detection of cardiac amyloid

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230920

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241202

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20241202

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260127

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20260316

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20260324

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20260316

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20260324

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260421